Lundbeck suffers Flurizan profit blow
This article was originally published in Scrip
Executive Summary
The clinical failure of Flurizan (tarenflurbil) hit Lundbeck heavily as charges relating to the drug more than halved the firm's second quarter net profit. The Danish company's profit fell by 52% to DKK240 million ($47.9 million) following a DKK481 million writedown related to the Alzheimer's disease candidate.